Short answer
Fulcrum Therapeutics, Inc. (FULC) filed its Q3 2026 10-Q quarterly report on Nov 12, 2026 for the quarter ended Sep 30, 2026.
Q3 2026 key financials · XBRL
- Net income
- −$11M
- +44.2% YoY · +58.2% QoQ
- EPS (diluted)
- −$0.14
- +54.8% YoY · +58.8% QoQ
Source: XBRL data from the Fulcrum Therapeutics, Inc. (FULC) Q3 2026 10-Q on SEC EDGAR. USD.
Fulcrum Therapeutics, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $0, unchanged YoY, with no product sales
- Net loss $10.9M vs $19.6M YoY, operating expenses $13.9M vs $21.9M
- Pociredir R&D expenses $1.9M vs $5.4M YoY, the largest program expense
- Cash, equivalents and securities $306.5M at September 30, 2026
- Operating cash used $48.2M vs $43.3M YoY, merger expected Q4 2026 with $275M dividend and $7.0M asset sale
Risk Factors
- Smaller reporting company status: Item 1A risk-factor disclosure omitted under Rule 12b-2
- No newly added, updated, regulatory, operational, competitive, market, or financial risks disclosed this quarter
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Fulcrum Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.